LISATA THERAPEUTICS, INC. — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors effective October 13, 2026, expanding the board from 7 to 8 members. Farrow, a veteran CFO with 15+ years of public-company experience including roles at Global Blood Therapeutics (acquired by Pfizer), ZS Pharma (acquired by AstraZeneca), and Hyperion Therapeutics (acquired by Horizon), will serve as an independent Class III director and join the Audit Committee. No cash compensation or equity grant amounts are disclosed in this filing.
Why this rating
Board appointment adds credible financial expertise relevant to late-stage biopharma, but is routine governance action with no economic impact disclosed; material relative to $23.6M market cap only if it signals major financing/strategic event ahead, which text does not indicate.
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.